608 related articles for article (PubMed ID: 31046702)
1. Predictive effects of body mass index on immune reconstitution among HIV-infected HAART users in China.
Li X; Ding H; Geng W; Liu J; Jiang Y; Xu J; Zhang Z; Shang H
BMC Infect Dis; 2019 May; 19(1):373. PubMed ID: 31046702
[TBL] [Abstract][Full Text] [Related]
2. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
3. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
[TBL] [Abstract][Full Text] [Related]
4. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
5. An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy.
Koethe JR; Jenkins CA; Shepherd BE; Stinnette SE; Sterling TR
Clin Infect Dis; 2011 Nov; 53(9):952-60. PubMed ID: 21946189
[TBL] [Abstract][Full Text] [Related]
6. The predictive role of CD4
Li CX; Li YY; He LP; Kou J; Bai JS; Liu J; Tian B; Cao LJ; Wang KH; Kuang YQ
BMC Immunol; 2019 Aug; 20(1):31. PubMed ID: 31455209
[TBL] [Abstract][Full Text] [Related]
7. Association of Body Composition and Other Clinical Factors with Incomplete Immune Response after Highly Active Antiretroviral Therapy.
Sun PT; Yu W; Li TS; Lin Q; Guo FP; Zhou XH; Du GY; Xu Y; Guan WM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):459-464. PubMed ID: 28877821
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
Sterling TR; Chaisson RE; Moore RD
AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
[TBL] [Abstract][Full Text] [Related]
9. Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort.
Rudy BJ; Lindsey JC; Flynn PM; Bosch RJ; Wilson CM; Hughes ME; Douglas SD;
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):213-21. PubMed ID: 16545007
[TBL] [Abstract][Full Text] [Related]
10. High baseline body mass index predicts recovery of CD4+ T lymphocytes for HIV/AIDS patients receiving long-term antiviral therapy.
Zhu J; Huang H; Wang M; Zhang Y; Mo J; Tian W; Tan S; Jiang L; Meng Z; Qin S; Ning C
PLoS One; 2022; 17(12):e0279731. PubMed ID: 36584083
[TBL] [Abstract][Full Text] [Related]
11. HIV DNA and immune alteration during successful HAART.
Mamadou D; Yu-Huang Z; Xia C; Bo H; Hua-Ying Z; Yan H; Zi C; Qing L; Li-Wen Z; Mei H; Yun-Hai Y; Demba S; Aldebert D; Souleymane M
Curr HIV Res; 2013 Jun; 11(4):255-62. PubMed ID: 23822818
[TBL] [Abstract][Full Text] [Related]
12. Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients.
Tedaldi EM; Brooks JT; Weidle PJ; Richardson JT; Baker RK; Buchacz K; Moorman AC; Wood KC; Holmberg SD;
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):35-41. PubMed ID: 16885779
[TBL] [Abstract][Full Text] [Related]
13. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
14. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV.
Grabar S; Kousignian I; Sobel A; Le Bras P; Gasnault J; Enel P; Jung C; Mahamat A; Lang JM; Costagliola D
AIDS; 2004 Oct; 18(15):2029-38. PubMed ID: 15577624
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status.
van Rossum AM; Scherpbier HJ; van Lochem EG; Pakker NG; Slieker WA; Wolthers KC; Roos MT; Kuijpers JH; Hooijkaas H; Hartwig NG; Geelen SP; Wolfs TF; Lange JM; Miedema F; de Groot R;
AIDS; 2001 Nov; 15(17):2267-75. PubMed ID: 11698700
[TBL] [Abstract][Full Text] [Related]
16. Immune reconstitution in HIV+ subjects on lopinavir/ritonavir-based HAART according to the severity of pre-therapy CD4+.
Marchetti G; Merlini E; Sinigaglia E; Iannotti N; Bai F; Savoldi A; Tincati C; Carpani G; Bini T; Arminio Monforte A
Curr HIV Res; 2012 Oct; 10(7):597-605. PubMed ID: 22716104
[TBL] [Abstract][Full Text] [Related]
17. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
18. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
Piriou E; Jansen CA; van Dort K; De Cuyper I; Nanlohy NM; Lange JM; van Oers MH; Miedema F; van Baarle D
J Immunol; 2005 Aug; 175(3):2010-7. PubMed ID: 16034146
[TBL] [Abstract][Full Text] [Related]
19. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
20. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
